4-羟基-7-碘-喹啉-3-羧酸 | 22200-49-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-羟基-7-碘-喹啉-3-羧酸
• 英文名称: 4-hydroxy-7-iodo-quinoline-3-carboxylic acid
• 英文别名: 4-Hydroxy-7-jod-chinolin-3-carbonsaeure；4-hydroxy-7-iodoquinoline-3-carboxylic acid；3-Quinolinecarboxylic acid, 4-hydroxy-7-iodo-；7-iodo-4-oxo-1H-quinoline-3-carboxylic acid
• CAS: 22200-49-3
• 化学式: C₁₀H₆INO₃
• 分子量: 315.067
• InChiKey: ZGLBZJRIKSFPNY-UHFFFAOYSA-N

物化性质

• 沸点：
  457.6±45.0 °C(Predicted)
• 密度：
  2.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-羟基-7-碘-喹啉-3-羧酸 在 三氯氧磷 作用下， 以 二苯醚 为溶剂， 反应 2.17h， 生成 4-氯-7-碘喹啉
  参考文献：
  名称：

  Structure−Activity Relationships for Antiplasmodial Activity among 7-Substituted 4-Aminoquinolines

  摘要：

  Aminoquinolines (AQs) with diaminoalkane side chains (-HNRNEt2) shorter or longer than the isopentyl side chain [-HNCHMe(CH2)(3)NEt2] of chloroquine are active against both chloroquine-susceptible and -resistant Plasmodium falciparum. (De, D.; et al. Am. J. Trop. Med. Hyg. 1996, 55, 579-583). In the studies reported here, we examined structure-activity relationships (SARs) among AQs with different N,N-diethyldiaminoalkane side chains and different substituents at the 7-position occupied by Cl in chloroquine. 7-Iodo- and 7-bromo-AQs with diaminoalkane side chains [-HN(CH2)(2)NEt2, -HN(CH2)(3)NEt2, or -HNCHMeCH2NEt2] were as active as the corresponding 7-chloro-AQs against both chloroquine-susceptible and -resistant P. falciparum (IC(50)s of 3-12 nM). In contrast, with one exception, 7-fluoro-AQs and 7-trifluoromethyl-AQs were less active against chloroquine-susceptible P. falciparum (IC(50)s of 15-50 nM) and substantially less active against chloroquine-resistant P. falciparum (IC(50)s of 18-500 nM). Furthermore, most 7-OMe-AQs were inactive against both chloroquine-susceptible (IC(50)s of 17-150 nM) and -resistant P. falciparum (IC(50)s of 90-3000 nM).

  DOI：

  10.1021/jm980146x
• 作为产物：
  描述：

  ethyl 7-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate 在 sodium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 0.75h， 以93%的产率得到4-羟基-7-碘-喹啉-3-羧酸
  参考文献：
  名称：

  Compounds and Methods of Treatment

  摘要：

  本文描述了一种作为Ret酪氨酸激酶抑制剂有用的衍生物。所述发明还包括使用相同物质治疗由不当的Ret酪氨酸激酶活性介导的疾病的方法。

  公开号：

  US20080234267A1

文献信息

• [EN] NOVEL QUINOLINE DERIVATIVES<br/>[FR] DERIVES NOUVEAUX DE QUINOLEINE
  申请人：PFIZER

  公开号：WO2005063739A1

  公开（公告）日：2005-07-14

  The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

  该发明涉及由式(I)表示的化合物，以及所述化合物的药学上可接受的盐或溶剂化合物，其中A、R3-8、X3、X5、m和n在此处被定义。该发明还涉及含有式(I)化合物的药物组合物，以及通过给予式(I)化合物治疗哺乳动物的增生性疾病的方法。
• Novel quinoline derivatives
  申请人：Hong Yufeng

  公开号：US20050137395A1

  公开（公告）日：2005-06-23

  The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R 3-8 , X 3 , X 5 , m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

  本发明涉及由公式(I)所代表的化合物，以及该化合物的药学上可接受的盐或溶剂，其中A、R3-8、X3、X5、m和n均在此定义。本发明还涉及含有公式(I)化合物的制药组合物，以及通过给哺乳动物注射公式(I)化合物来治疗增生性疾病的方法。
• NOVEL QUINOLINE DERIVATIVES
  申请人：Hong Yufeng

  公开号：US20090069316A1

  公开（公告）日：2009-03-12

  The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R 3-8 , X 3 , X 5 , m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

  该发明涉及由公式（I）表示的化合物，以及该化合物的药学上可接受的盐或溶剂，其中在此定义了A、R3-8、X3、X5、m和n中的每个。该发明还涉及包含公式（I）化合物的药物组合物，以及通过给予公式（I）化合物来治疗哺乳动物的过度增殖性疾病的方法。
• Synthesis of novel anilinoquinolines as c-fms inhibitors
  作者：Terrence L. Smalley、Stanley D. Chamberlain、Wendy Y. Mills、David L. Musso、Sab A. Randhawa、John A. Ray、Vicente Samano、Lloyd Frick

  DOI：10.1016/j.bmcl.2007.09.009

  日期：2007.11

  A novel series of potent substituted anilinoquinolines were discovered as c-fms inhibitors. The potency could be manipulated upon modification of the C4 aniline and C7 aryl functionality. Pharmacokinetic analysis identified a metabolically stable analog suitable for further investigative work. (C) 2007 Elsevier Ltd. All rights reserved.
• Heterocyclic Basic Compounds. XII. 7-Bromo-and 7-Iodo-quinolines
  作者：A. E. Conroy、Harry S. Mosher、Frank C. Whitmore

  DOI：10.1021/ja01177a504

  日期：1949.9